Approved for use through 07/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless if displays a valid OMB control number.

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)						
Title of	MIDAZOLE-BASED HMG-COA REDUCTASE INHIBITORS					
Invention						
	amed inventor(s), I/we declare that:					
This declaration	n is directed to:					
	The attached application, (and Preliminary Amendment, if applicable), or					
	Application No, filed on					
	as amended on (if applicable);					
I/we believe that sought;	I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is					
	ed and understand the contents of the above-identified application, including the claims, as amended by any cifically referred to above;					
material to paten	e the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be tability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which be between the filing date of the prior application and the national or PCT International filing date of the art application.					
	WARNING					
Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioner/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.  All statements made herein of my/own knowledge are true, all statements made herein on information and belief are believed to						
	ner that these statements were made with the knowledge that willful false statements and the like are punishable onment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing					
Full Name of I	nventor(s)					
Inventor 1	Mark Richard Bush					
Signature	Citizen of US					
Inventor 2	Michael David Kaufman					
Signature	Citizen of					
★ Additional in	ventors are being named on					

Burden Hour Statement: This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is used by the public to file (and the PTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This form is estimated to take 1 minute to complete. This time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Approved for use through 07/31/2006. OMB 0651-0032 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patern and Trauemark Onice, U.S. Patern and Trauemark Onice, U.S. Del Alliand OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless if displays a valid OMB control number.

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)								
Title of Invention	IMIDAZOLE-BASED HMG-COA REDUCTASE INHIBITORS							
As the below r	As the below named inventor(s), I/we declare that:							
This declaration	n is directed to:							
	The attached application, (and Preliminary Amendment, if applicable), or							
	Application No, filed on							
	as amended on (if applicable);							
I/we believe tha sought;	I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is							
	ved and understand the contents of the above-identified application, including the claims, as amended by any cifically referred to above;							
material to pate	ge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be natability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which e between the filing date of the prior application and the national or PCT International filing date of the part application.  WARNING							
Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioners/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.								
All statements made herein of my/own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.								
Full Name of	nventor(s)							
Inventor 3	Richard H Hutchings							
Signature	Citizen of US							
Inventor 4	Robert Michael Kennedy							
Signature	Citizen of							
Additional in	oventors are being named on							

Burden Hour Statement: This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is used by the public to file (and the PTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This form is estimated to take 1 minute to complete. This time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/01A (10-05)
Approved for use through 07/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless if displays a valid OMB control number.

APPLICATION DATA SHEET (37 CFR 1.76)								
Title of I	MIDAZOLE-BASED HMG-COA REDUCTASE INHIBITORS							
	As the below named inventor(s), I/we declare that:							
This declaration	n is directed to:							
	The attached application, (and Preliminary Amendment, if applicable), or							
	Application No, filed on							
	as amended on (if applicable);							
I/we believe that sought;	I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is							
	red and understand the contents of the above-identified application, including the claims, as amended by any cifically referred to above;							
material to paten	I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT International filing date of the							
	WARNING							
Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioners/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.  All statements made herein of my/own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.								
Full Name of I	nventor(s)							
Inventor 5	Scott D Larson							
Signature	Citizen of US							
Inventor 6	Toni Jo Poel							
Signature	Citizen of							
X Additional in	ventors are being named on							

Burden Hour Statement: This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is used by the public to file (and the PTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This form is estimated to take 1 minute to complete. This time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

## Approved for use through 07/31/2006. OMB 0651-0032 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless if displays a valid OMB control number. DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN **APPLICATION DATA SHEET (37 CFR 1.76)** IMIDAZOLE-BASED HMG-COA REDUCTASE INHIBITORS Title of Invention As the below named inventor(s), I/we declare that: This declaration is directed to: 冈 The attached application, (and Preliminary Amendment, if applicable), or Application No. \_\_\_\_\_, filed on \_\_\_\_\_ as amended on \_\_\_\_\_ (if applicable); I/we believe that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought; I/we have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment specifically referred to above; I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT International filing date of the continuation-in-part application. WARNING Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioners/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available. All statements made herein of my/own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon. Full Name of Inventor(s) Inventor 7 Yuntao Song US Signature Citizen of \_ Inventor 8 **Bharat K Trivedi** Signature Citizen of

Burden Hour Statement: This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is used by the public to file (and the PTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This form is estimated to take 1 minute to complete. This time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Additional inventors are being named on

PTO/SB/81(06-03)

Approved for use through 11/30/2005. OMB 0651-0035
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

		Applicat	ion Numbe	г		
POWER OF ATTORNEY			ite			
			ned Invent	or	Mark Richard Bush	
and					IMIDAZOLE-BASED HMG-COA REDUCTASE INHIBITORS	
CORRESPONDE	Art Unit	-		TILL SOUTH OF THE STATE OF THE		
INDICATION	ON FORM	Examine	r Name			
		Attorney	Docket Nu	ımber	PC25862	
I hereby appoint:						
Practitioners at Custor	mer Number	2888	<u>o</u>		•	
OR COR						
Practitioners named b	elow:					
	Name	· ·	F	Registrati	on Number	
•						
as my/our attorney(s) or age	nt(s) to prosecute the application s Patent and Trademark Office o	n identified	above, and	to transact	all	
	the correspondence address for		' '	polication t	٥٠	
The above-mentioned	·	the above	identified a	pplication		
OR	Customer Number.					
				٦		
The address associate	ed with Customer Number		*	<b>」</b>		
OR						
Firm or Individual Name						
Address						
Address						
City		S	tate		Zip	
Country		•	_			
Telephone		Fa	×		•	
I am the:					-	
Applicant/Inventor.						
Assignee of record of Statement under 37 C	the entire interest. See 37 CFR 3 FR 3.73(b) is enclosed. (Form P	3.71. <i>TO/SB/96)</i> .				
	SIGNATURE of App	olicant or	Assignee	of Reco	rd	
Name	Mark Richard Bush					
Signature						
Date						
NOTE: Signatures of all the inveforms if more than one signature		the entire in	terest or the	eir represe	ntative(s) are required. Submit multiple	
□ *Total of forms are submitted.						

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

•		Applicat	ion Numb	er	
÷		Filing Da	ate		
POWER OF ATTORNEY and			med Inven	tor	Mark Richard Bush
					IMIDAZOLE-BASED HMG-COA REDUCTASE INHIBITORS
	NCE ADDRESS	Art Unit		-	
INDICATION	ON FORIVI	Examine	r Name		
		Attorney	Docket N	umber	PC25862
I hereby appoint:				_	
Practitioners at Custo	mer Number	2888	80	]	
OR				ı	
Practitioners named b	elow:				
	Name			Registrati	on Number
as my/our attorney(s) or age business in the United State	nt(s) to prosecute the application s Patent and Trademark Office c	n identified a	above, and	l to transact	all
	the correspondence address for			application t	0:
The above-mentioned					
OR	-			_	
The address associate	ed with Customer Number				
Firm or Individual Name					
Address		•			
Address				-	
City		S	tate		Zip
Country					
Telephone		Fa	×		
I am the:					
Applicant/Inventor.					
	the entire interest. See 37 CFR 3 FR 3.73(b) is enclosed. (Form P				
	SIGNATURE of App	olicant or	Assigne	e of Recor	rd .
Name	Michael David Kaufman			-	
Signature					
Date					
NOTE: Signatures of all the inveforms if more than one signature	entors or assignees of record of t e is required, see below*.	the entire in	terest or th	eir represer	ntative(s) are required. Submit multiple
Total of forms are submitted.					

PTO/SB/81(06-03)

Approved for use through 11/30/2005. OMB 0651-0035
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

		Applicati	on Number		
		Filing Da	e		
POWER OF	ATTORNEY	First Nan	ed Inventor	Mark Richard Bush	
and CORRESPONDENCE ADDRESS				IMIDAZOLE-BASED HM REDUCTASE INHIBITO	
INDICATION	Art Unit				
INDICATION	Examine	Name			
<u>-</u>		Attorney	Docket Number	PC25862	
I hereby appoint:					
Practitioners at Custon	mer Number	2888	)		
OR					
Practitioners named b	elow:				
	Name		Registrat	ion Number	]
					-
					1
					]
as my/our attorney(s) or age	nt(s) to prosecute the applications S Patent and Trademark Office	on identified a	bove, and to transac	t all	
			<del></del>	<b>1</b> 0.	
	the correspondence address for	or the above-	аепшеа аррісацоп	ю.	
The above-mentioned	Customer Number.				
OR	_				
The address associate	ed with Customer Number				
OR					
Firm or Individual Name					
Address				N Control of the Cont	
Address					
City		St	ate	Zip	
Country				<u>.                                    </u>	
Telephone		. Fax	:		
I am the:					
Applicant/Inventor.			·		
	the entire interest. See 37 CFF FR 3.73(b) is enclosed. (Form				
	SIGNATURE of A		Assignee of Reco	rd	
Name	Richard H Hutchings				
Signature		·			
Date					
NOTE: Signatures of all the inve forms if more than one signature		f the entire in	erest or their represe	ntative(s) are required.	Submit multiple
☐ *Total of forms are su					
<del></del>					

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

	Application Number				
	Filing Date				
POWER OF ATTORNEY	First Named	Inventor	Mark Richard Bush		
and	Title		IMIDAZOLE-BASED HMG REDUCTASE INHIBITORS		
CORRESPONDENCE ADDRESS	Art Unit				
INDICATION FORM	Examiner Na	ame			
	Attorney Do	cket Number	PC25862		
I hereby appoint:		•			
Practitioners at Customer Number	28880			ļ	
OR					
Practitioners named below:					
Name		Registrati	ion Number		
as my/our attorney(s) or agent(s) to prosecute the application business in the United States Patent and Trademark Office or	identified abov	e, and to transact	all		
Please recognize or change the correspondence address for					
The above-mentioned Customer Number.	the above iss.	.ппои пррпостог. ,.	<b>o</b> .		
OR					
The address associated with Customer Number					
OR					
Firm or Individual Name					
Address					
Address					
City	State	T	Zip		
Country .					
Telephone	Fax				
I am the:		<u> </u>			
Applicant/Inventor.					
Assignee of record of the entire interest. See 37 CFR 3 Statement under 37 CFR 3.73(b) is enclosed. (Form P					
SIGNATURE of App		signee of Recor	rd		
Name Robert Michael Kennedy					
Signature					
Date					
NOTE: Signatures of all the inventors or assignees of record of the forms if more than one signature is required, see below*.	he entire intere	st or their represer	ntative(s) are required. Su	ıbmit multiple	
Total of forms are submitted.					

PTO/SB/81(06-03)

Approved for use through 11/30/2005. OMB 0651-0035
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

		Application	Number			
POWER OF ATTORNEY		Filing Date				
		First Named	Inventor	Mark Richard Bush		
ar	Title		IMIDAZOLE-BASED HMG-COA REDUCTASE INHIBITORS			
	CORRESPONDENCE ADDRESS					
INDICATION	INDICATION FORM					
		Attorney Do	cket Number	PC25862		
I hereby appoint:  Practitioners at Custon  OR	28880		·			
Practitioners named b	elow:					
	Name		Registrati	on Number		
as my/our attorney(s) or age business in the United State	nt(s) to prosecute the application s Patent and Trademark Office co	identified abo	ve, and to transact with.	all		
Please recognize or change the correspondence address for the above-identified application to:  The above-mentioned Customer Number.  OR  The address associated with Customer Number						
Firm or Individual Name						
Address						
Address						
City		State		Zip		
Country						
Telephone		Fax				
I am the:  Applicant/Inventor.  Assignee of record of the entire interest. See 37 CFR 3.71.  Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96).						
	SIGNATURE of App	licant or As	signee of Reco	'd		
Name	Scott D Larson					
Signature						
Date						
NOTE: Signatures of all the inve forms if more than one signature	entors or assignees of record of the is required, see below*.	he entire intere	st or their represer	ntative(s) are required. Submit multiple		
☐ *Total of forms are su	bmitted.					

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

		Application Number			
POWER OF ATTORNEY and CORRESPONDENCE ADDRESS			ate	-	
			med Invent	or	Mark Richard Bush
					IMIDAZOLE-BASED HMG-COA REDUCTASE INHIBITORS
INDICATION	ON FORIVI	Examine	er Name		
		Attorney	/ Docket N	umber	PC25862
I hereby appoint:					
Practitioners at Custon	mer Number	2888	30		
OR	<u></u>				
Practitioners named b	elow:				
	Name			Registrati	on Number
				-	
as my/our attorney(s) or age business in the United State	nt(s) to prosecute the application s Patent and Trademark Office o	n identified	above, and herewith.	to transact	all .
	the correspondence address for			pplication to	0:
The above-mentioned	·			,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	••
OR	Oustomer Number.				
	ed with Customer Number			7	
OR	<u> </u>			<b>-</b>	
П <b>г</b>					
Firm or Individual Name	•		•		
Address					
Address					
City		s	tate		Zip
Country					
Telephone-		Fa	ıx		
I am the:		•		•	
Applicant/Inventor.					
Assignee of record of Statement under 37 C	the entire interest. See 37 CFR ( FR 3.73(b) is enclosed. (Form F	3.71. <i>PTO/SB/96)</i>			
	SIGNATURE of App	plicant or	Assignee	of Reco	rd
Name	Toni Jo Poel				
Signature					
Date					
NOTE: Signatures of all the inve forms if more than one signature		the entire ir	nterest or th	eir represer	ntative(s) are required. Submit multiple
*Total of forms are su	bmitted.				

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

		Application Number				
		Filing Dat	.e			
POWER OF	ATTORNEY	First Nam	ed Invent	or	Mark Richard Bush	
ar		Title			IMIDAZOLE-BASED HMG REDUCTASE INHIBITOR	
	CORRESPONDENCE ADDRESS INDICATION FORM					
INDICATION	JN FORIVI	Examiner	Name	-		
		Attorney	Docket N	umber	PC25862	
I hereby appoint:						
Practitioners at Custon	mer Number	28880	)	ı		
OR	<u></u>					
Practitioners named b	elow:					
_	Name			Registrati	on Number	
as my/our attorney(s) or age	ent(s) to prosecute the application s Patent and Trademark Office c	n identified al	bove, and	to transact	all	
	the correspondence address for			polication to	O'	
The above-mentioned	•	1 810 422.2	20.11	ppnounce	<b>.</b>	
OR	Customer Number.					
The address associate	ed with Customer Number					· .
Firm or Individual Name						
Address						
Address						
City		Sta	ite		Zip	
Country						
Telephone		Fax			·	
I am the:  Applicant/Inventor.	the entire interest. See 37 CFR 3	0 71				·
Statement under 37 C	FR 3.73(b) is enclosed. (Form P	PTO/SB/96).				
	SIGNATURE of App	plicant or A	\ssignee	of Recor	rd	
Name	Yuntao Song		_		•	
Signature						
Date	· 					
NOTE: Signatures of all the inve forms if more than one signature	entors or assignees of record of t e is_required, see below*.	the entire inte	erest or the	eir represen	ntative(s) are required. S	ubmit multiple
*Total of forms are su	bmitted.					

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

	Application Number					
	Filing Date	,				
POWER OF ATTORNEY	First Name	ed Invent	or	Mark Ric	hard Bush	
and	Title				E-BASED HM	
CORRESPONDENCE ADDRESS	Art Unit					
INDICATION FORM	Examiner	Name				
	Attorney D	ocket Nu	ımber	PC2586	2	
I hereby appoint:						
Practitioners at Customer Number	28880	ı				
OR						
Practitioners named below:						
Name		F	Registrati	on Numb	er	]
						ļ
						<b>j</b>
· L						J
as my/our attorney(s) or agent(s) to prosecute the application business in the United States Patent and Trademark Office co	identified ab	ove, and	to transact	all		
Please recognize or change the correspondence address for t	-		polication to	n·		
The above-mentioned Customer Number.	ille above .c.	Cittinou w	ррпоцион	<b>u</b> .		
OR	•					
			7			
The address associated with Customer Number						
OR						
Firm or Individua! Name						
Address						
Address						
City	Stat	ie		Zip		
Country						
Telephone	Fax					
I am the:						
Applicant/Inventor.						
Assignee of record of the entire interest. See 37 CFR 3. Statement under 37 CFR 3.73(b) is enclosed. (Form PT						
SIGNATURE of Appl		ssignee	of Recor	ď		·
Name Bharat K Trivedi		-				
Signature						
Date						
NOTE: Signatures of all the inventors or assignees of record of th forms if more than one signature is required, see below*.	e entire inte	rest or the	eir represer	ntative(s) a	re required. S	ubmit multiple
*Total of forms are submitted.						